3月2日 - ** Alaunos Therapeutics TCRT.O股价大涨18.8%至3.79美元
** 药物开发商称其实验性药物ALN1003在临床前研究中帮助肥胖小鼠减轻了体重；肥胖是一种以体内脂肪过多为特征的慢性疾病
** 公司称，小鼠体重最多减轻了 13%，肝脏组织也更加健康
** 该公司称，这种药物与 GLP-1 药物不同，不含激素；高脂肪饮食的小鼠进食更少，减掉的脂肪也更多
** 出现了轻微、暂时的活动变化；两只高剂量小鼠轻微脱水，但很健康。
** 2025 年股价上涨 70%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.